BIO-Europe Spring® 2016: Selexis CEO talks licensing, academic partnerships and biosimilars

May 10, 2016
Dr. Igor Fisch, CEO of Selexis SA, a drug discovery and cell-line development services company, speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about Selexis' focus on biologics and its business model centered on licensing deals. During BIO-Europe Spring 2016 in Stockholm, Sweden, the pair discuss Selexis' unique selling point, how the company works with academia to produce innovative technology, and how the growing biosimilars market might affect the business in coming years.
Previous Video
BIO-Europe Spring® 2016: ORYX CEO on research partnerships and cancer vaccine studies
BIO-Europe Spring® 2016: ORYX CEO on research partnerships and cancer vaccine studies

Bernard Huber, CEO and founder of ORYX Translational Medicine, and Mike Ward, global director of content fo...

Next Video
BIO-Europe Spring® 2016: How to get Takeda Ventures to notice your startup
BIO-Europe Spring® 2016: How to get Takeda Ventures to notice your startup

Dr. Ilan Zipkin, senior investment director at Takeda Ventures, talks with Mike Ward, global director of co...